Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis
2019 · Expert Opinion on Drug Metabolism & Toxicology · 36 citations
https://doi.org/10.1080/17425255.2019.1681969
F
Federico Diotallevi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
98
Papers
1.5K
Citations
21
h-index
40
i10-index
Federico Diotallevi is an academic researcher from Marche Polytechnic University. The author has contributed to research in topics: Psoriasis: Treatment and Pathogenesis & Dermatology and Skin Diseases & Dermatological and COVID-19 studies. The author has an h-index of 21, co-authored 84 publications.
ORCID: 0000-0003-2274-1742Papers by this author
worksDimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic
2022 · Dermatology and Therapy · 10 citations
https://doi.org/10.1007/s13555-022-00684-3
Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy
2021 · Dermatology and Therapy · 7 citations
https://doi.org/10.1007/s13555-021-00610-z
InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study
2023 · Dermatology and Therapy · 7 citations
https://doi.org/10.1007/s13555-023-00931-1
Clinical‐epidemiological aspects of the Monkeypox 2022 epidemic: A multicentre study by the Italian SIDeMaST Group of Sexually Transmitted, Infectious and Tropical Diseases
2023 · Journal of the European Academy of Dermatology and Venereology · 3 citations
https://doi.org/10.1111/jdv.19265
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.20129514
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat